Acquisition Announced
J&J acquisition of FireFly Biologics
US$1bn consideration
Announced 2026 (approx.)
Advisers
J&J
Acquirer
Not disclosed
- Target
- FireFly Biologics
- Acquirer
- J&J
- Target based in
- United States (unverified)
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Oncology
In the league tables
Similar deals
- Novartis acquisition of Myricx Bio Jul 2026 · US$1.1bn · Biotech
- Amgen acquisition of Dark Blue Therapeutics Jan 2026 · US$840m · Biotech
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- AstraZeneca acquisition of AbelZeta's 50% share of China development and commercialisation rights to C-CAR031 Jan 2026 · US$630m · Biotech
- Novartis acquisition of Pikavation Mar 2026 · US$2bn · Biotech
Sources
- 2026 Centerview Partners: Exclusive financial advisor to Firefly Bio on its sale to J&J centerviewpartners.com
